[ad_1]
HYDERABAD: Pharma major Dr Reddy’s Laboratories is foraying into the trade generics business in the Indian market with the rollout of a new dedicated division — RGenX, under which the company will be selling these unbranded medicines that are copycat versions of innovator drugs which have gone off-patent.
The Hyderabad-based company said it will roll out its trade generics business across cities, towns and rural areas across the country by working closely with channel partners to ensure availability of its products.
The focus, to start with, will be on acute segment products such as respiratory and anti-infectives. The business will work on a model driven by channel partners wherein the retailer will push the medicines instead of a prescription-driven model.
“We aspire to break into top 5 players in the domestic market. To that end, we are trying to build a well-rounded business in India – between branded generics, trade generics, collaborations, and Horizon 2 opportunities,” a Dr Reddy’s spokesperson said.
The Hyderabad-based company said it will roll out its trade generics business across cities, towns and rural areas across the country by working closely with channel partners to ensure availability of its products.
The focus, to start with, will be on acute segment products such as respiratory and anti-infectives. The business will work on a model driven by channel partners wherein the retailer will push the medicines instead of a prescription-driven model.
“We aspire to break into top 5 players in the domestic market. To that end, we are trying to build a well-rounded business in India – between branded generics, trade generics, collaborations, and Horizon 2 opportunities,” a Dr Reddy’s spokesperson said.
#Reddys #enters #generics #business #India #market
